Argá Medtech SA Nets $58.5M Series B to Revolutionize Cardiac Ablation with Non-Thermal Energy Innovation

Argá Medtech SA is thrilled to announce a major milestone in our journey toward revolutionizing cardiac care with a successful funding round that raised CHF 58,520,000. This significant investment underscores our commitment to innovate and redefine the landscape of cardiac ablation treatments on a global scale. As a privately-held medical device company based in Switzerland and formed by a team of seasoned industry leaders, we have consistently pushed the boundaries of scientific research and technology to meet the pressing needs of patients suffering from cardiac arrhythmias and atrial fibrillation. Our cutting-edge approach leverages Pulsed Electrical Fields (PEF) technology to create irreversible electroporation (IRE) of cardiomyocytes, marking a departure from traditional thermal ablation techniques. The infusion of capital is poised to accelerate the development of our non-thermal energy-based cardiac ablation system, which promises a safer, faster, and more cost-effective treatment option for millions of patients worldwide. In addition to advancing our device through the necessary regulatory pathways and clinical trials, the funding will also support scaling our operational capabilities, expanding our research and development team, and strengthening partnerships with key stakeholders in the healthcare ecosystem. This infusion of resources empowers Argá Medtech SA to push forward with a clear vision—addressing unmet medical needs, enhancing patient outcomes, and transforming the treatment of cardiac arrhythmias. Ultimately, our goal is to deliver a novel and far-reaching solution that not only sets new standards in cardiac care but also affords healthcare providers a reliable tool in the ongoing battle against heart rhythm disorders.